369593-35-1

Upstream product

• 543-27-1 isobutyl chloroformate 
• 103201-79-2 (3R,7aS)-3-phenyl-tetrahydro-pyrrolo[1,2-c]oxazol-5-one 

Downstream Products

• 369593-36-2 isobutyl (3S,6S,7R,7aR)-7-(4-fluorophenyl)-3-phenyl-5-oxo-tetrahydro-1H,3H-pyrrolo[1,2-c]oxazole-6-carboxylate 
• 369593-37-3 isobutyl (3S,4R,5S)-1-benzyl-4-(4-fluorophenyl)-5-(hydroxymethyl)pyrrolidine-3-carboxylate 
• 369593-38-4 isobutyl (3S,4R,5S)-1-benzyl-5-chloro-4-(4-fluorophenyl)piperidine-3-carboxylate 
• 369593-39-5 isobutyl (3S,4R)-1-benzyl-4-(4-fluorophenyl)piperidine-3-carboxylate 
• 201855-60-9 (3S,4R)-[1-benzyl-4-piperidin-3-yl-4-(4-fluorophenyl)]methanol 
• 503552-80-5 (2S,3R,4S)-1-benzyl-3-(4-fluorophenyl)pyrrolidine-2,4-bismethanol 

Relevant academic research and scientific papers

Ring expansion: Formal total synthesis of (-)-paroxetine

A ring expansion and a radical dehalogenation have been used as the key steps in a formal total synthesis of (-)-paroxetine. A stereoselective ring expansion of prolinol generated the substituted piperidine ring precursor of (-)-paroxetine.